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Background: Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival
for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or
docetaxel (Doc), but not zoledronic acid (ZA), were added to androgen-deprivation therapy (ADT). Trial evidence also suggests a
benefit of combining celecoxib (Cel) with ZA and ADT. To establish the optimal treatments, a network meta-analysis (NMA) was
carried out based on aggregate data (AD) from all available studies.
Methods: Overall survival (OS) and failure-free survival data from completed Systemic Treatment Options for Cancer of the
Prostate reviews of Doc, ZA and AAP and from recent trials of ZA and Cel contributed to this comprehensive AD-NMA. The
primary outcome was OS. Correlations between treatment comparisons within one multi-arm, multi-stage trial were estimated
from control-arm event counts. Network consistency and a common heterogeneity variance were assumed.
Results: We identified 10 completed trials which had closed to recruitment, and one trial in which recruitment was ongoing, as
eligible for inclusion. Results are based on six trials including 6204 men (97% of men randomised in all completed trials).
Network estimates of effects on OS were consistent with reported comparisons with ADT alone for AAP [hazard ration
(HR)¼ 0.61, 95% confidence interval (CI) 0.53–0.71], Doc (HR¼ 0.77, 95% CI 0.68–0.87), ZAþCel (HR¼ 0.78, 95% CI 0.62–0.97),
ZAþDoc (HR¼ 0.79, 95% CI 0.66–0.94), Cel (HR¼ 0.94 95% CI 0.75–1.17) and ZA (HR¼ 0.90 95% CI 0.79–1.03). The effect of
ZAþCel is consistent with the additive effects of the individual treatments. Results suggest that AAP has the highest probability
of being the most effective treatment both for OS (94% probability) and failure-free survival (100% probability). Doc was the
second-best treatment of OS (35% probability).
Conclusions: Uniquely, we have included all available results and appropriately accounted for inclusion of multi-arm,
multi-stage trials in this AD-NMA. Our results support the use of AAP or Doc with ADT in men with metastatic hormone-naive
prostate cancer. AAP appears to be the most effective treatment, but it is not clear to what extent and whether this is due to a
true increased benefit with AAP or the variable features of the individual trials. To fully account for patient variability across trials,
changes in prognosis or treatment effects over time and the potential impact of treatment on progression, a network meta-
analysis based on individual participant data is in development.
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Introduction
Numerous randomised controlled trials (RCTs) have evaluated
or are currently evaluating, the addition of other therapies to an-
drogen-deprivation therapy (ADT) in men with metastatic
hormone-naive prostate cancer (mHNPC). To determine reliably
which are effective, we are conducting a series of systematic re-
views under the auspices of the Systemic Treatment Options for
Cancer of the Prostate (STOPCAP) collaboration. Our prior
STOPCAP systematic reviews showed improved survival when
abiraterone acetate plus prednisolone/prednisone (AAP) or
docetaxel (Doc), but not zoledronic acid (ZA), were added to
ADT [1, 2]. Trial evidence also suggests a benefit of combining
celecoxib (Cel) with ZA and ADT [3].
However, only the reported comparisons of the STAMPEDE
multi-arm, multi-stage (MAMS) platform and the ongoing
Prostate Cancer Consortium in Europe (PEACE)-1 trial
(NCT01957436) will be able to provide head-to head results com-
paring these therapies. Network meta-analysis [4, 5], which takes
advantage of both direct and indirect comparisons, is therefore
needed to determine reliably which is the optimal treatment(s),
and so to inform patients, clinicians and policy makers. We have
therefore conducted a systematic review and network meta-
analysis of aggregate data (AD) to assess the optimal systemic
treatments for men with mHNPC, making use of existing
STOPCAP reviews [1, 2] and up-to-date results from individual
trials, and also taking account of the MAMS platform design of
the STAMPEDE trial protocol.
Methods
The full protocol for this review was registered in July 2017 (http://www.
crd.york.ac.uk/PROSPERO/display_record.asp? ID¼CRD42017071811,
1 March 2018, date last accessed).
Eligibility criteria
The eligibility criteria for inclusion in this network meta-analysis mirror
those in prior systematic reviews [1, 2]. In brief, eligible trials should have
been randomised in a way which precluded prior knowledge of the treat-
ment assigned and compared ADT alone with ADT in combination
with any of the agents (or combinations of agents) under consider-
ation, namely celecoxib (Cel), zoledronic acid (ZA), celecoxib and
zoledronic acid (ZAþCel), docetaxel (Doc), zoledronic acidþ docetaxel
(ZAþDoc) or abiraterone acetate plus prednisolone (AAP). The men
randomised were diagnosed with mHNPC, and either starting or respond-
ing to the first-line ADT for metastatic disease (they may have received
prior treatments for early, localised disease). Trials were also eligible if they
met the above criteria but additionally co-administered supportive treat-
ments on the experimental arm only. Trials were excluded if they had rand-
omised men who had castration-resistant prostate cancer or if they had
included additional first-line treatments only on the control arm only.
Trial identification
As part of the wider STOPCAP project, we regularly and systematically
search a number of sources to identify all published, unpublished and on-
going trials in mHNPC, providing a comprehensive and up-to-date data-
base of all RCTs eligible for all of our STOPCAP systematic reviews.
We also request regular updates from relevant trial teams on the status
and reporting plans. Thus, all trials included in our previous STOPCAP
reviews [1, 2] and any additional RCTs meeting the eligibility criteria
were included.
In summary, we searched MEDLINE, EMBASE, clinicaltrials.gov
and the Cochrane Central Register of Controlled Trials (CENTRAL),
using database-specific search strategies. We also searched proceedings
from relevant conferences. In addition, reference lists of review art-
icles and bibliographies of identified trial reports were screened for
further eligible trials. Full search strategies have been previously
reported [1, 2].
Outcomes
The primary outcome was overall survival (OS), with failure-free survival
(FFS) the secondary outcome.
Data extraction
The principal data extracted or derived from included studies was the log
hazard ratio and SE or the information to estimate them [e.g. a hazard
ratio (HR) and confidence interval (CI) or P value [6] for OS and FFS].
Outcome definitions were also extracted for each trial to ensure their
consistency and the appropriateness of combining results in a formal
meta-analysis. Additional summary data including start and end dates of
recruitment, details of treatment schedules on the control and experi-
mental arms, numbers of patients and their demographics were also
extracted, either directly from the trial publications or from prior system-
atic reviews.
Assessing the risk of bias of included trials
Assessment of study quality for all trials included in the prior STOPCAP
reviews was previously carried out in the individual reviews, using the
Cochrane risk of bias tool [7] and all included studies were assessed as
having low risk of bias based on reported information and study proto-
cols [8]. Risk of bias assessments for additional eligible studies identified
for inclusion in the network meta-analysis was also carried out using the
Cochrane tool.
Analysis
One of the trials identified as eligible for inclusion, the STAMPEDE trial,
used a MAMS platform design. The nature of this type of design means
that some patients randomised to the control arm contribute to multiple
pairwise treatment comparisons within the trial. Therefore, to appropri-
ately include data from this trial in an AD network meta-analysis, we
needed to assess the correlations between the effect estimates arising due
to periods of overlap in the common control arm. Correlations were
estimated using the control-arm event counts within the periods of
overlap for which data were obtained directly from the STAMPEDE
investigators.
The primary analysis was carried out using a frequentist contrast-
based network meta-analysis model and the network suite of com-
mands [5] in Stata v14.1 (StataCorp, Texas, USA). Because all trials in
this network, apart from the MAMS trial, are two-arm comparisons with
the common control arm, any test for inconsistency would assess hetero-
geneity between the MAMS and other studies. Therefore, we fitted a con-
sistency model and assessed heterogeneity, assuming a common
heterogeneity variance across all comparisons. In the primary analysis, all
comparisons of treatment combinations (e.g. ADTþZAþDoc versus
ADT) were assumed to be unrelated to the comparisons of their compo-
nent treatments (e.g. ZA and Doc). A sensitivity analysis assumed addi-
tive treatment effects.
A network map (Figure 1) was constructed to display all of the avail-
able relationships, with distinct treatments represented by nodes, and tri-
als (or separate trial comparisons within the single MAMS design trial)
by lines joining appropriate nodes. The thickness of the lines, represent-
ing the extent of available data for each comparison, was estimated
from the combined number of events for all trials contributing to each
individual comparison. Borrowing of strength statistics, which represent
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the proportion of the information for each treatment comparison that
the indirect evidence from the network model has contributed, were
calculated using the score decomposition method [9].
Estimates of relative effect for each pairwise treatment comparison
from the primary consistency model were estimated on the HR scale
along with corresponding 95% confidence limits and displayed in a
network forest plot [5]. Treatment rankings were also calculated and
summarised as a surface under the cumulative rank (SUCRA) value, rep-
resenting the re-scaled mean ranking [10]. Further detailed methods
relating to all the planned analyses may be found in the Statistical
Analysis Plan (available on request).
Finally, we conducted an indirect comparison of the two most effective
treatments to estimate the relative difference in the size of the effects. We
estimated the absolute benefit of treatment on OS at 3 years by applying
the HR estimates to the approximate survival at 3 years.
Role of the funding source
The funders of the study (Medical Research Council and Prostate Cancer
UK) had no role in study design, data collection, data analysis, data inter-
pretation or writing of the report. The corresponding author had full ac-
cess to all the data in the study and had final responsibility for the
decision to submit for publication.
Results
Description of the included trials
Searches undertaken for the STOPCAP project identified 11 trials
that were eligible for inclusion in the network meta-analysis. Five
of these 11 eligible trials could not be included in the network
meta-analysis. Of these five, two trials that together randomised
72 men to receive ADT or ADT plus doc and two trials that to-
gether randomised 102 men to receive ADT versus ADT plus ZA
identified as eligible for a previous STOPCAP review [2] could
not be included here as they had not yet presented results for sur-
vival outcomes. The fifth trial, PEACE-1 (NCT01957436),
comparing standard of care with or without AAP continues to re-
cruit towards a target of 1168 men and no results are currently
available for inclusion.
Therefore, six RCTs that had reported results were included
in the network meta-analysis (Figure 1, Table 1). Two trials
compared ADT with ADT plus ZA; two compared ADT with
ADT plus Doc and one trial compared ADT with ADT plus
AAP. The final trial, STAMPEDE [11], contributed six separate
treatment comparisons [3, 12, 13] to the network. Four com-
parisons were of ADT with Cel, ZA, Doc or AAP and two fur-
ther comparisons were of ADT with combinations of ZA
plus Cel or ZA plus Doc. Importantly, although each of the six
comparisons shared a common control arm, there was some
non-contemporaneous recruitment to individual treatment
comparisons. In total, 6204 men were included in the network
meta-analysis, representing 97% of men randomised in all com-
pleted eligible trials (at least 83% of men randomised in all 11
eligible trials). Accounting for the shared control arm patients
in the STAMPEDE trial, 2615 men were randomised to receive
ADT alone, and 3589 men were randomised to receive ADT in
combination with one of the treatments being considered in the
network.
OS and FFS were reported for all of the treatment comparisons.
The definition of FFS included time to prostate specific antigen
(PSA) or clinical progressionor death for all of the trials, except
LATITUDE [14], which did not include time to PSA progression
and CHAARTED [15], which did not include time to death.
Further details of the trials, including the definitions used for
FFS, are given in Table 1.
Borrowing of strength from the network
Inclusion in the network led to a gain in information for each of
the pairwise treatment comparisons (Table 2). For OS, this
ranged from 0.9% (AAP) to 9.2% (ZAþDoc). For FFS, the gains
ADT + AAP
Published comparisons from
sources other than STAMPEDE
Published (or derivable directly from published)
comparisons from James et al. Lancet 2016
Published (or derivable directly from published)
comparisons from Mason et al. JCO 2017
Published comparison from James et al. NEJM 2017
Unpublished STAMPEDE comparisons
with overlap in control-arm (ADT) patients
Key:
ADT + ZA
ADT + ZA + DocADT + Doc
ADT + Cel
ADT + ZA + Cel
ADT alone
Figure 1. Network meta-analysis structure. AAP, abiraterone acetate plus prednisolone/prednisone; ADT, androgen-deprivation therapy; Cel,
celecoxib; Doc, docetaxel; ZA, zoledronic acid.
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were generally greater and ranged from 6.7% (Doc) to 21.7%
(ZAþDoc).
Overall survival
The network meta-analysis HR estimates suggested that
compared with ADT alone each of AAP (HR¼ 0.61, 95% CI
0.53–0.71), Doc (HR¼ 0.77, 95% CI 0.68–0.87), ZAþDoc
(HR¼ 0.79, 95% CI 0.66–0.94) and ZAþCel (HR¼ 0.78, 95%
CI 0.62–0.97) in combination with ADT improved survival.
There was no survival advantage observed with ADT in combin-
ation with either ZA (HR¼ 0.90, 95% CI 0.79–1.03) or Cel (0.94,
95% CI 0.75–1.17) over ADT alone. For the comparisons of ADT
versus ADTþCel, ADTþZAþCel and ADTþZAþDoc, the
only data available were from single comparisons within the
STAMPEDE trial [3, 13]. There was no evidence of heterogeneity
between the effects of treatment within any of the individual
treatment comparisons and all of the estimates from the network
analysis were in keeping with those obtained in the previously
reported pairwise meta-analyses where available (Figure 2).
Treatment rankings
When used in combination with ADT, AAP has the highest prob-
ability (94%) of being the most effective treatment, Doc has a
35% probability of being the second-best treatment and ADT
alone has the highest probability of being the least effective treat-
ment (67%, Table 3).
Failure-free survival
There was an FFS benefit associated with adding ADT to each
of AAP (HR¼ 0.38 95% CI 0.31–0.46), Doc (HRþ 0.64 95%
CI 0.54–0.75) and ZAþDoc (HR¼ 0.63 95% CI 0.49–0.80)
compared with ADT alone. No statistically significant benefit was
Table 1. Description of included trials (or treatment comparisons from the STAMPEDE trial) and FFS deﬁnition used in the trial. All trials had a control arm
of ADT
Trial Recruitment
period
Median
follow-up
(months)
Treatment Treatment
(N)
Control
(N)
Definition of FFS
CALGB 90202
[21]
June 2004 to
April 2012
Unknown ADT þ ZA 323 322 Time to ﬁrst bone progression, PSA
progression, or death
GETUG 15 [22] Oct 2004 to
Dec 2008
84 ADT þ Doc 192 193 Time to PSA progression, clinical
progression or death
STAMPEDE
(Arms A
versus D) [3]
Oct 2005 to
April 2011
69 ADT þ Cel 188 377 Time to PSA failure, progression of local,
lymph-node, or distant metastases; or
death from prostate cancer
STAMPEDE
(Arms A
versus F) [3]
Oct 2005 to
April 2011
69 ADT þ ZA þ Cel 190 377 Time to PSA failure, progression of local,
lymph-node, or distant metastases; or
death from prostate cancer
STAMPEDE
(Arms A
versus B) [13]
Oct 2005 to
March 2013
43 ADT þZA 366 724 Time to PSA failure, progression of local,
lymph-node, or distant metastases; or
death from prostate cancer
STAMPEDE
(Arms A
versus C) [13]
Oct 2005 to
March 2013
43 ADT þ Doc 362 724 Time to PSA failure, progression of local,
lymph-node, or distant metastases; or
death from prostate cancer
STAMPEDE
(Arms A
versus E) [13]
Oct 2005 to
March 2013
43 ADT þ ZA þ Doc 365 724 Time to PSA failure, progression of local,
lymph-node, or distant metastases; or
death from prostate cancer
CHAARTED [23] July 2006 to
Dec 2012
54 ADT þ Doc 397 393 Time to PSA rise or clinical progression
ZAPCA (KYUH
TRIG0705)
[24]
May 2008 to
Dec 2010
42 ADT þZA 109 110 Time to earliest date of PSA progression,
clinical progression, ﬁrst SRE, death for
any reason, or cessation of protocol
treatment for any reason
STAMPEDE
(Arms A
versus G) [12]
Nov 2011- Jan
2014
40 ADT þ AAP 500 502 Time to PSA failure, progression of local,
lymph-node, or distant metastases; or
death from prostate cancer
LATITUDE [14] Feb 2013 to
Dec 2014
30 ADT þ AAP 597 602 Time to radiographic progression or death
from any cause
AAP, abiraterone acetate plus prednisolone/prednisone; ADT, androgen-deprivation therapy; Cel, celecoxib; Doc, docetaxel; FFS, failure-free survival;
SRE, skeletal related events; ZA, zoledronic acid.
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seen with the addition of Cel (HR¼ 0.89 95% CI 0.67–1.17);
ZAþCel (HR¼ 0.80 95% CI 0.60–1.05) or ZA alone (HR¼ 0.88
95% CI 0.75–1.05). In all cases, the HR estimates obtained
through the network were very similar to those obtained using a
standard pairwise meta-analysis, providing confirmation that the
network model is behaving as expected. There was evidence of
variation or inconsistency between the effects of treatment within
the individual treatment comparisons of ADT versus ADT plus
AAP (I2¼91%, heterogeneity P¼ 0.001) where there was a large
variation between the size of the relative effects (but not the
direction of the effect) observed between the two included trial
comparisons. However, there was no evidence of variation or in-
consistency between the effects of treatment within the remaining
treatment comparisons, and all of the estimates from the network
analysis were in keeping with those obtained in the previously re-
ported pairwise meta-analyses where available (Figure 3).
Therefore, we carried out a sensitivity analysis using the out-
come of time to PSA failure as reported in LATITUDE to assess
the robustness of our primary analysis. This analysis, whilst not
changing our interpretation, did result in an HR estimate from
the network analysis was slightly more in favour of treatment
(HR¼ 0.30, 95% CI 0.27–0.34) with no evidence of variation of
inconsistency (I2¼0, heterogeneity P¼ 0.78).
Based on the treatment rankings, when combined with ADT,
AAP has the highest probability (100%) of being the most effective
treatment in terms of FFS, whilst either Doc alone (45% probabil-
ity) or in combination with ZA (52% probability) is most likely to
be the second-best treatment. ADT alone has the highest probabil-
ity of being the least effective treatment (73%, Table 4).
Indirect comparison of the two most effective
treatments
When used in combination with ADT, two treatments, AAP and
Doc, emerged as being effective in terms of improving both OS
and FFS relative to ADT alone, and with the greatest probabilities
of being the top two most effective treatments; therefore, they were
compared indirectly in a pairwise comparison. The HR estimate
for the effect of ADTþAAP relative to the effect of ADTþDoc on
OS is 0.80 (95% CI 0.66–0.96). Assuming a baseline OS of 60% at
3 years with ADTþDoc, this translates to an absolute survival
benefit associated with AAP of 6% (95% CI¼ 1% to 11%), that is,
to 66% at 3 years (95% CI 61% to 71%). For FFS, the HR for the
effect of ADTþAAP relative to ADTþDoc is 0.59 (95% CI
0.46–0.75) (Figure 4).
Discussion
Summary of results
Based on the current data, either AAP or Doc alongside ADT im-
proves the survival of men with mHNPC. Although AAP has the
highest probability of being the most effective treatment, with
DocþADT the second most effective treatment, uncertainty re-
mains about the difference in absolute magnitude of survival
benefit between these two treatments (between 1% and 9% at
3 years). Adding ZAþDoc or ZAþCel to ADT also improved
survival relative to ADT alone.
Strengths
This is the first network meta-analysis to comprehensively assess
and rank the effects of all the systemic treatments for mHNPC
recently tested in RCTs. By working with trial investigators, we
have been able to make use of the most up-to-date, and consistent
AD from six trials and 6204 men, representing 97% of those
randomised in reported, eligible trials. Thus, it provides the most
reliable assessment of the relative effects of these agents to date.
In particular, our analysis has been able to shed light on the
comparison of AAP and Doc in conjunction with ADT and has
also reinforced the observed survival benefit associated with the
combination of Cel and ZA, although not with either of these
agents given individually [3]. Furthermore, to the best of our
knowledge, this is the first example of a network meta-analysis
that has taken account of the complexities of including a MAMS
platform trial, appropriately adjusting the analysis for the
proportion of the control-arm patients common to different
pairwise comparisons. Obtaining limited unpublished informa-
tion direct from the investigators made this possible.
Limitations
Whilst we have been comprehensive in our approach to this
review, relying on AD inevitably has limitations. For example,
whilst most trials include PSA progression as part of the defin-
ition of FFS, the LATITUDE trial [14] presented results for PSA
failure and clinical or radiological progression separately. Whilst
our pre-specified primary analysis used time to clinical or radio-
logical progression for the LATITUDE trial, a sensitivity analysis
which used time to PSA failure data from LATITUDE showed
that our results are robust to these different definitions. In hind-
sight, although this might have been the preferable primary
analysis, it would have made little difference to our interpretation
and conclusions.
There are differences in the patient characteristics, which may
influence the effects of the various treatments either within or
across trials. Despite these differences, however, there has been
no clear evidence of heterogeneity in the effects of zoledronic
acid, docetaxel or abiraterone across trials in the individual
STOPCAP systematic reviews [1, 2]. Nevertheless, some of the
Table 2. Borrowing of strength statistics (% of information gained per
pairwise analysis through inclusion in the network)
Comparison OS, % FFS
ADT versus ADT þCel 5.4 17.3
ADT versus ADT þ ZA 3.9 7.7
ADT versus ADT þ ZA þ Cel 5.2 17.1
ADT versus ADT þ Doc 2.0 6.7
ADT versus ADT þ ZA þ Doc 9.2 21.7
ADT versus ADT þ AAP 0.9 7.4
AAP, abiraterone acetate plus prednisolone/prednisone; ADT, androgen-
deprivation therapy; Cel, celecoxib; Doc, docetaxel; FFS, failure-free sur-
vival; OS, overall survival; ZA, zoledronic acid.
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individual trials have suggested treatment–covariate interactions,
notably that the effects of Doc may be moderated by the extent of
metastatic disease volume and that the effects of AAP may be
associated with age [1, 12]. There are no well-defined methods to
appropriately assess such interactions in an AD network meta-
analysis. Therefore, they will be best investigated through the col-
lection and re-analysis of individual participant data from all of
the eligible trials, which the STOPCAP collaborators are currently
working to undertake.
Context
Previously, both Doc and AAP have been shown to improve
survival and delay progression in men with mHNPC [2, 16].
However, as no trials have set out to directly compare ADT plus
docetaxel with ADT plus AAP, network meta-analysis provides
the only comprehensive approach to this treatment comparison.
However, the design of the STAMPEDE trial, in which treatments
were simultaneously compared against ADT alone, has enabled
an opportunistic analysis in which outcomes for men
randomised within the same time frame to receive ADT plus Doc
or ADT plus AAP were compared [17]. Whilst not a fully pow-
ered analysis, the results demonstrated an advantage of AAP over
Doc with respect to FFS (HR¼ 0.51, 95% CI 0.39–0.67,
P< 0.001), which did not translate to a survival benefit
(HR¼ 1.16, 95% CI 0.82–1.65, P¼ 0.40). It is not clear why the
findings of the STAMPEDE analysis differ with respect to OS
from the findings of the network meta-analysis. The STAMPEDE
analysis is a direct comparison of men who were randomised con-
temporaneously to receive either AAP or Doc in addition to
ADT. The network meta-analysis has considerably more power
to detect differences in treatment effects, due to both the inclu-
sion of more trials and more men, and the additional strength
that other treatment comparisons lend within the network.
However, the inclusion of more trials, that randomised men to
receive a variety of treatments over a longer time period inevit-
ably brings with it greater variability, due to the broader case mix
of patients, with different prognoses, and with differing access to
treatments after progression of disease. It has not been possible in
this analysis to account for changes in care over time, particularly
AAP+ADT vs ADT
ZA+Doc+ADT vs ADT
Doc+ADT vs ADT
ZA+Cel+ADT vs ADT
ZA+ADT vs ADT
Cel+ADT vs ADT
Treatment comparison and study
Pairwise (I2=0%; Heterogeneity p=0.91)
Network
STAMPEDE
LATITUDE
Network
STAMPEDE
Pairwise (I2=0%; Heterogeneity p=0.52)
Network
STAMPEDE
GETUG 15
CHAARTED
Network
STAMPEDE
Pairwise (I2=0%; Heterogeneity p=0.77)
Network
ZAPCA (KYUH TRIG0705)
STAMPEDE
CALGB 90202
Network
STAMPEDE
Hazard Ratio (95% CI)
0.62 (0.53, 0.71)
0.61 (0.53, 0.71)
0.61 (0.49, 0.75)
0.62 (0.51, 0.76)
0.79 (0.66, 0.94)
0.79 (0.66, 0.95)
0.77 (0.68, 0.88)
0.77 (0.68, 0.87)
0.76 (0.62, 0.93)
0.88 (0.68, 1.14)
0.73 (0.59, 0.90)
0.78 (0.62, 0.97)
0.78 (0.62, 0.98)
0.90 (0.78, 1.03)
0.90 (0.79, 1.03)
0.78 (0.49, 1.24)
0.93 (0.77, 1.12)
0.88 (0.70, 1.11)
0.94 (0.75, 1.17)
0.94 (0.75, 1.18)
Favours                        
treatment+ADT                        
Favours
ADT alone
0.25 0.50 1.00 2.00
Figure 2. Overall survival. Forest plot of network and pairwise estimates of treatment effects [all treatments compared with androgen-depriv-
ation therapy (ADT) alone]. AAP, abiraterone acetate plus prednisolone/prednisone; CI, conﬁdence interval; Cel, celecoxib; Doc, docetaxel; ZA,
zoledronic acid.
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whilst the number of new treatments available at relapse has rap-
idly increased, and once again this is best achieved through the
collection and analysis of individual participant data.
Other network meta-analyses have been reported. Feyerabend
et al. [18] presented the results of an indirect comparison of AAP
and Doc based on the results of just two trials. Wallis et al. [19]
Table 3. Treatment ranking (% probability) and SUCRA values based on overall survival results
AAP Doc ZA1Doc ZA1Cel ZA Cel ADT alone
Best 94.2 0.7 1.3 3.8 0.0 0.0 0.0
Second best 5.3 34.9 25.5 33.0 0.3 1.0 0.0
Third best 0.4 36.8 30.3 27.0 2.4 3.1 0.0
Fourth best 0.1 23.6 30.8 23.9 12.2 9.3 0.1
Fifth best 0.0 3.8 9.3 9.3 48.7 26.0 2.9
Sixth best 0.0 0.2 2.6 2.5 31.3 33.6 29.8
Worst 0.0 0.0 0.2 0.5 5.1 27.0 67.2
SUCRA 1.0 0.7 0.6 0.6 0.3 0.2 0.1
AAP, abiraterone acetate plus prednisolone/prednisone; ADT, androgen-deprivation therapy; Cel, celecoxib; Doc, docetaxel; SUCRA, surface under the cu-
mulative rank; ZA, zoledronic acid.
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Figure 3. Failure-free survival. Forest plot of network and pairwise estimates of treatment effects [all treatments compared with androgen-
deprivation therapy (ADT) alone]. AAP, abiraterone acetate plus prednisolone/prednisone; CI, conﬁdence interval; Cel, celecoxib; Doc,
docetaxel; ZA, zoledronic acid.
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have also reported indirect comparisons of ADT plus AAP
with ADT plus Doc. However, we have concerns regarding the
methodological approaches used by the authors, in particular,
the inclusion of patients with and without metastases; the
double-counting of shared control arm patients, and therefore
correlations, from the STAMPEDE trial and the use of flawed
subgroup analysis methodology [20].
Finally, a key question that remains for both clinicians and pa-
tients is whether the two most effective treatments, AAP and Doc,
could be safely combined and if so, what the impact of the com-
bination may be on OS. This question will only be resolved when
results from the ongoing PEACE-1 trial are available.
Conclusions
Our results support the use of either AAP or Doc alongside ADT in
men with mHNPC. AAP appears to be the most effective treatment,
but it is not clear to what extent and whether this is due to a true
increased benefit with AAP or to the variable features of the individ-
ual trials. To fully account for patient variability across trials,
changes in prognosis or treatment effects over time, and the poten-
tial impact of treatment on progression, a network meta-analysis
based on individual participant data is currently in development.
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